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Since October 2015 up to September 2016, HIV diag-
noses fell by 32% compared with October 2014–
September 2015 among men who have sex with men 
(MSM) attending selected London sexual health clin-
ics. This coincided with high HIV testing volumes and 
rapid initiation of treatment on diagnosis. The fall was 
most apparent in new HIV testers. Intensified testing 
of high-risk populations, combined with immediately 
received anti-retroviral therapy and a pre-exposure 
prophylaxis (PrEP) programme, may make elimination 
of HIV achievable.
Gay, bisexual and other men who have sex with men 
(MSM) account for half of all people living with HIV in 
England and are the group most at risk of acquiring HIV 
[1]. By end 2015, 94% (34,439/37,590) of MSM diag-
nosed with HIV in England received anti-retroviral ther-
apy (ART), of whom 95% had supressed viral load (viral 
load < 200 mL) [1]. An additional 5,000–8,000 MSM 
were estimated to have undiagnosed infection [1-3].
Since 2012, national guidelines have recommended 
up to 3-monthly HIV testing for MSM at high risk of 
acquiring HIV [4,5] and starting ART regardless of CD4 
count to prevent onward transmission (‘treatment as 
prevention’) [6,7]. Consequently, the number of men 
starting ART rose from 2,700 in 2013 to 3,600 in 2015 
[1]. Beginning in 2013, pre-exposure prophylaxis (PrEP) 
has been available to some MSM as part of the ‘Pre-
exposure prophylaxis to prevent the acquisition of HIV-1 
infection (PROUD)’ trial [8] and more recently through 
international purchasing online [9,10]. In December 
2016, selected London sexual health clinics reported a 
fall in HIV diagnoses among MSM [11]. A rapid analysis 
of surveillance and monitoring data was conducted to 
confirm and explain this fall.
Data sources and analysis
Quarterly data from the genitourinary medicine 
clinic activity dataset (GUMCADv2) for January 2013–
September 2016 [12] were used to examine HIV diag-
noses and testing patterns among MSM attending one 
of the over 200 free, confidential, open-access sexual 
health clinics in England. Clinics that reported a large 
fall in diagnoses in the most recent year for which data 
were available, i.e. clinics with a > 20% decline and > 40 
cumulative new HIV diagnoses between October 2014–
September 2015 and October 2015–September 2016, 
were compared with other clinics in London and out-
side London. The number of HIV-negative MSM attend-
ing with a history of an HIV test and a bacterial sexually 
transmitted infection (STI) (> 90% were genital or rectal 
infections) was used as an indicator for those at high 
risk of HIV acquisition.
The HIV and AIDS Reporting System (HARS) [13] data, 
geographically aligned for clinics, for the most recent 
years (2013–2015) were used to examine: (i) trends 
in CD4 count within 91 days of HIV diagnosis; (ii) the 
number of MSM diagnosed with HIV who are untreated 
or treated but whose viral load is not suppressed; and 
(iii) time from HIV diagnosis to ART initiation. National 
estimates of HIV prevalence were stratified by the pro-
portion of diagnosed and undiagnosed infection [3]. 
Estimates of the proportion of MSM with undiagnosed 
HIV infection [1] were calculated using the number of 
MSM with diagnosed infection to estimate the number 
of those undiagnosed in the catchment area of each 
clinic group.
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Fall in HIV diagnoses among men who have 
sex with men
Between October 2014–September 2015 and October 
2015–September 2016, reported new HIV diagno-
ses among MSM fell by 17% (from 2,060 to 1,707) in 
England and by 25% (from 1,227 to 915) in London. 
Nationally, diagnoses among heterosexuals remained 
stable at 1,500 in both periods. A 32% decline was 
observed among five London large-fall clinics (from 
880 to 595; p = 0.014 for test of linear trend in diagno-
ses by quarter) compared with 8% at 30 other London 
clinics (from 347 to 320, p = 0.115) and 5% (from 833 
to 792, p = 0.101) in 191 clinics in the rest of England 
(Figure 1,2).
Changing patterns of HIV testing
Testing patterns were analysed from January 2013–
September 2016. Among the large-fall clinics (Figure 
2a), the number of HIV tests in MSM increased by 50% 
(from 8,820 in January–March 2013 to 14,820 in July–
September 2016); the number of new testers, i.e. those 
not tested in the previous 2 years, was stable at around 
5,000 per quarter, whereas the number of repeat test-
ers i.e. those who had an HIV test within the previous 
2 years increased by 60%, from 4,800 to 9,760. The 
3-year rise in testing in the large-fall clinics coincided 
with an initial increase in HIV diagnoses through 2014 
in both new and repeat testers and in early 2015 the 
decline was observed, predominantly in new testers. 
In other London clinics, the number of new and repeat 
Figure 1
New HIV diagnoses among men who have sex with men attending sexual health clinics by year and quarter, England, 
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BASHH: British Association for Sexual Health and HIV; BHIVA: British HIV Association; MSM: men who have sex with men; PrEP: pre-exposure 
prophylaxis; PROUD: Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection; Q = quarter.
a Defined as clinics with at least a 20% decrease in HIV diagnoses and over 40 cumulative diagnoses between October 2014–September 2015 
and October 2015–September 2016.
P1: Recruitment to the PROUD trial began with 50% of participants allocated to the deferred arm (12 months after trial commenced) [8].  P2: All 
deferred participants offered PrEP.  P3: Online purchasing of PrEP began in late 2015.  P4: Online purchasing of PrEP routine. Interpolating 
from the trial enrolment figures over time [5], an estimated 200 MSM were taking PrEP by end 2013, 500 by end 2014, and it is likely an 
additional few hundred by end 2016 with the majority of the latter via online purchase [9,10,14,15].
G1: In May 2012 BHIVA/ BASHH and in November 2012, Public Health England (at the time, the Health Protection Agency) recommended that 
high-risk MSM have an HIV test annually and up to every 3 months if having condomless sex with new or casual partners.
G2: In May 2012, BHIVA guidelines advised people could start ART with a CD4 count > 350 cells after discussion with the clinician should the 
patient wish to protect partners from sexual HIV transmission.
G3: In September 2015, BHIVA guidelines were strengthened to recommend treatment for all individuals regardless of CD4 count for the 
purpose of treatment as prevention.
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testers remained stable, and outside London, new and 
repeat testers increased equally, although there was 
no discernible effect on HIV diagnoses in either setting 
(Figure 2b and c).
Over the period, the number of MSM attending clinics 
increased by 4% for both groups of London clinics, and 
by 16% outside of London. Importantly, the volume 
of testing at the large-fall clinics was such that 41% 
(58,180/140,980) of HIV tests in MSM attending clin-
ics in England during October 2015–September 2016 
occurred at one of these five clinics. Exceptionally, the 
median CD4 count at HIV diagnosis of men diagnosed 
at large-fall clinics increased substantially (from 469 in 
2013 to 548 in 2015). In contrast, the median CD4 count 
rose only from 442 to 489 in other London clinics, and 
remained around 430 outside London, over the same 
period. This indicates that the testing volumes and 
frequency of testing carried out in these settings were 
still insufficient to substantially reduce the average 
time from infection to diagnosis compared with large-
fall clinics.
Prompt treatment following HIV diagnosis
Although the number of MSM living with diagnosed 
HIV infection who were untreated declined by 27% 
in England (from 4,025 in 2013 to 2,950 in 2015), this 
decline was greatest at large-fall clinics (51%; from 
1,224 to 601) compared with other London clinics 
(17%; from 906 to 754) and clinics outside London 
(16%; from 1,895 to 1,595) (Figures 3a-c). Moreover, 
while there has been a general reduction in the time 
to starting ART in those with a CD4 count > 350 at onset 
of ART, the median time from diagnosis to treatment in 
2015 was substantially shorter at large-fall clinics (120 
days) compared with other London clinics (190 days) 
and clinics outside London (260 days) (Figures 3d-f).
Men who have sex with men with transmissible 
levels of virus
MSM with transmissible levels of virus include those 
diagnosed who are untreated or treated with a viral 
load > 200 copies/mL, as well as those with an undi-
agnosed infection (Figure 3a-c). In 2015, there were 
an estimated 10,190 MSM with transmissible levels 
of virus in England: 29% (n = 2,950) untreated, 34% 
(n = 3,420) unsuppressed and 37% (n = 3,820) undiag-
nosed. In the same year, among clinic attendees, the 
ratio of MSM with transmissible levels of virus to MSM 
at high-risk of HIV acquisition was 0.6 (2,088/3,596) 
at large-fall clinics, 2.6 (2,219/868) at other London 
clinics and 2 (5,877/2,933) at clinics outside London. 
Assuming that sexual networks broadly correspond 
with clinic attendance patterns, the documented ratio 
differences suggest that MSM at high risk of HIV acqui-
sition who attended one of the large-fall clinics have a 
Figure 2
Number of HIV tests and diagnoses in men who have sex with men at sexual health clinics by new and repeat tests and 
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Numbers of men who have sex with men living with HIV infection who are undiagnosed, diagnosed and untreated or 
treated and non-supressed viral load (A-C) and median time (days) from HIV diagnosis to ART initiation, by CD4 count at 























































































































































































B. Other London sexual health clinics (n=30)











D. London large-fall sexual health clinics (n=5)
E. Other London sexual health clinics (n=30)
Undiagnosed >350 <350Unsuppressed Untreated
ART: anti-retroviral therapy; MSM: men who have sex with men.
Treatment data and viral load data are adjusted for missing information (99% and 84% respectively): CD4 cell count taken within 91 days of 
diagnosis, available for 91% (7,519/8,297) of records; CD4 count at ART initiation, available for 76% (6,960/9,150) of records. Year-specific 
estimates of proportion of all MSM with HIV who are undiagnosed were obtained using Multi-Parameter Evidence Synthesis [1,3].
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much lower likelihood of exposure to a man with trans-
missible levels of virus.
Availability of pre-exposure prophylaxis
Available data suggest the number of MSM who began 
PrEP in England either as trial participants or via online 
purchase has been limited to date. Although all five 
large-fall clinics participated in the PROUD trial, three 
other clinics in London and five clinics outside London 
did so as well. An estimated 200 MSM were taking PrEP 
by end 2013, 500 by end 2014 [8,14] and it is likely an 
additional few hundred by end 2016 [9,10,15].
Assuming a best prevention case scenario of a 9% 
annual HIV incidence, the very high-risk level as 
observed in the PROUD trial [8], by end 2015, the 
cumulative number of HIV infections directly prevented 
by PrEP would have been 90 at most. Not all of them 
would have attended large-fall clinics and of those who 
did, the decline in directly prevented infections would 
have been most apparent in repeat HIV testers.
Limitations
Though powerful, the surveillance and monitoring data 
needs cautious interpretation, especially given the 
post-hoc nature of the analysis. Conclusions could be 
affected by reporting delay (albeit minimal), incom-
plete data in relation to ART coverage, ART start date 
and CD4 count at HIV diagnosis, and neither the impact 
of partner notification nor the movement between clin-
ics for HIV testing is measured. The assumption that 
attendees of the same clinics are more likely to form 
part of the same sexual network compared with ran-
dom sexual mixing is plausible but unsubstantiated. 
Finally, while numbers of HIV diagnoses are not syn-
onymous with HIV incidence, the rise in median CD4 
count at HIV diagnosis suggests that the fall in diagno-
ses reflects a fall in incidence.
Conclusions
The 17% fall in new HIV diagnoses in MSM in England 
between October 2014–September 2015 and October 
2015–September 2016 was focussed in five clinics 
which experienced a 32% decline. The fall seen at 
these five clinics coincided with accelerated treatment 
at diagnosis and a substantial increase in HIV testing, 
particularly repeat testing.
The volume of HIV tests across London combined with 
rapid treatment following diagnosis at the five large-
fall clinics is now likely to have reached a level that 
decreases the number of men with transmissible levels 
of virus thereby reducing transmission. The use of PrEP 
among high-risk MSM, although limited at this stage, 
will also have contributed to the fall in new diagnoses. 
If HIV testing of MSM at high risk of HIV is intensified, 
and wide-scale immediate ART, as observed within the 
London large-fall clinics, is replicated elsewhere, it 
is probable that a substantial reduction in HIV trans-
mission among MSM could be achieved nationally. 
Should the promise of the ‘PrEP Impact Trial’ proposed 
in England [16] be realised promptly, then a very 
large reduction in HIV transmission in MSM may be 
attained. The similarity of the MSM HIV epidemic in 
England to elsewhere in western Europe [17] suggests 
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